title: SureClick® (Darbepoetin alfa) can improve perceived satisfaction and competence for anemia treatment and increase self-administration in non-dialyzed patients with chronic kidney disease.
abstract: OBJECTIVE
  SureClick® is a prefilled pen for administration of darbepoetin alfa (DA) that is ready-to-use. We explored patient satisfaction with SureClick® compared with prefilled syringes (PFS).
  
  
  METHODS
  Multicenter, prospective, 6-months, observational study in non-dialyzed patients with chronic kidney disease (CKD) treated with DA in PFS who switched to SureClick® at baseline. Main outcomes were: change in Anemia Treatment Satisfaction Questionnaire (ATSQ-S), Perceived Competence for Anemia Scale (PCAS) and self-administration rate.
  
  
  RESULTS
  We enrolled 132 patients with a mean(SD) age of 71.3 (14.6) years, 57.6% women. Mean(SD) ATSQ-S scores at baseline and final records were 25.5 (7.9) and 31.6 (4.9) (on a scale from 0 to 36 maximum satisfaction-, mean change: 6.2, 95%CI: 4.6-7.8, p<0.0001). The PCAS also increased significantly (4.3 (2.0) vs 5.6 (1.6), on a scale from 1 to 7 maximum competence, p<0.0001). At baseline 47.7% of patients self-administered DA with PFS, vs 74.2% with SureClick® (p<0.001). No significant changes in hemoglobin were observed (11.4 (0.5) vs 11.6 (1.3) g/dl, p=0.193). Two patients (1.5%) had adverse reactions to SureClick® (pain on application).
  
  
  CONCLUSIONS
  Our results suggest that the change from PFS to SureClick® could increase patient satisfaction and perceived competence in anemia management in non-dialyzed CKD patients, and could increase the self-administration rate, thereby reducing use of health resources.
authors.affiliation: Servicio de Farmacia, Hospital Universitari Germans Trías i Pujol. Badalona, Barcelona, Spain. xbonafont.germanstrias@gencat.cat
authors.forename: Xavier
authors.initials: X
authors.lastname: Bonafont
authors.forename: Ramón
authors.initials: R
authors.lastname: Romero
authors.forename: Isabel
authors.initials: I
authors.lastname: Martínez
authors.forename: María D
authors.initials: MD
authors.lastname: del Pino
authors.forename: José M
authors.initials: JM
authors.lastname: Gil
authors.forename: Pedro
authors.initials: P
authors.lastname: Aranda
authors.forename: Ramón
authors.initials: R
authors.lastname: Roca
authors.forename: Joana
authors.initials: J
authors.lastname: Claverol
authors.forename: Mercedes
authors.initials: M
authors.lastname: Cucala
mesh_terms: D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000068256:Darbepoetin alfa; D004867:Equipment Design; D004921:Erythropoietin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D017060:Patient Satisfaction; D011446:Prospective Studies; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications; D012646:Self Administration / Q000295:instrumentation / Q000706:statistics & numerical data; D011795:Surveys and Questionnaires; D013594:Syringes
chemical_list: D006397:Hematinics; D004921:Erythropoietin; D000068256:Darbepoetin alfa